{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:46:21Z","timestamp":1787021181642,"version":"build-2736575974"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,6,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Integrin beta-6 (IB6) is highly expressed in non\u2013small cell lung cancer (NSCLC) and other solid tumors and potentially associated with poor outcomes. Sigvotatug vedotin (SV), a novel IB6-directed antibody-drug conjugate, demonstrated acceptable safety and encouraging antitumor activity in dose escalation. We report updated results for dose-expansion regimens in advanced NSCLC (aNSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>SGNB6A-001 is an open-label, multicenter, dose-escalation\/dose-expansion phase I study evaluating safety, tolerability, pharmacokinetics (PK), and antitumor activity of SV in patients with select advanced solid tumors. After dose escalation, dose expansion further explored three regimens: 1.25 mg\/kg total body weight (TBW) on Days 1 and 8 of a 21-day cycle, 1.5 mg\/kg TBW on Days 1 and 15 of a 28-day cycle (once every 2 weeks), and 1.8 mg\/kg adjusted ideal body weight (AiBW) once every 2 weeks. Eligible patients had prior chemotherapy and immunotherapy or targeted therapy if indicated. Primary end points were safety and determination of an optimal dosing schedule. Secondary end points were antitumor activity, PK, and immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>As of November 26, 2024, 117 patients with aNSCLC were treated in the above cohorts. Any-grade and grade \u22653 treatment-emergent adverse events occurred in 98% and 48% of all patients, respectively, and in 94% and 35% of patients receiving SV 1.8 mg\/kg AiBW once every 2 weeks. Modeling revealed that the AiBW regimen resulted in lower PK variability than TBW regimens. The objective response rate and median duration of response were 19% and 11.3 months in the overall population, respectively, and 29% and 12.8 months in patients with nonsquamous, taxane-na\u00efve NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>SV demonstrated a manageable safety profile and promising antitumor activity with durable responses in aNSCLC. PK and clinical data support further investigation with the recommended 1.8-mg\/kg AiBW once every 2 weeks dosing regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-02016","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:59:41Z","timestamp":1776715181000},"page":"1635-1645","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6\u2013Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non\u2013Small Cell Lung Cancer"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":true,"given":"Solange","family":"Peters","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-1660","authenticated-orcid":true,"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4391-6943","authenticated-orcid":true,"given":"Kartik","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-829X","authenticated-orcid":true,"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[{"name":"START Madrid-CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-1560","authenticated-orcid":true,"given":"Bruno","family":"Bockorny","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8139-8215","authenticated-orcid":false,"given":"Vladimir","family":"Galvao","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institute of Oncology (VHIO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-6839","authenticated-orcid":true,"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-9355","authenticated-orcid":true,"given":"Elisa","family":"Fontana","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute UK, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3459-871X","authenticated-orcid":true,"given":"Tatiana","family":"Hernandez-Guerrero","sequence":"additional","affiliation":[{"name":"START Barcelona-HM Nou Delfos, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rivera Herrero","sequence":"additional","affiliation":[{"name":"Oncology, Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Kingsley","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Centers of Nevada, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8321-4212","authenticated-orcid":true,"given":"Juanita S.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4144-2193","authenticated-orcid":false,"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[{"name":"The START Center for Cancer Research, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5860-4921","authenticated-orcid":true,"given":"Cesar Augusto","family":"Perez","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute at Florida Cancer Specialists\u2014Lake Nona, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-6054","authenticated-orcid":true,"given":"Rachel E.","family":"Sanborn","sequence":"additional","affiliation":[{"name":"Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1645-9315","authenticated-orcid":true,"given":"Scott","family":"Knowles","sequence":"additional","affiliation":[{"name":"Pfizer, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5795-0547","authenticated-orcid":true,"given":"Gabriela","family":"Patilea-Vrana","sequence":"additional","affiliation":[{"name":"Pfizer, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8774-826X","authenticated-orcid":true,"given":"Jerry","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimo","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer, Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7551","authenticated-orcid":true,"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_11_3_2","unstructured":"American Cancer Society: Key statistics for lung cancer. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00277"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132350"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0817"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012346"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0174"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1453"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32137"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0245"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu474"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2007.09.008"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2168"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S274892"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2307"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115534"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3024"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8521"},{"key":"e_1_3_11_20_2","first-page":"731","article-title":"A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: Interim results of a phase 1 study (SGNB6A-001)","volume":"10","author":"Hollebecque A","year":"2022","unstructured":"Hollebecque A, Lopez JS, Piha-Paul SA, et al: A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: Interim results of a phase 1 study (SGNB6A-001). J Imunother Cancer 10:731, 2022 (suppl)","journal-title":"J Imunother Cancer"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115281"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02157.x"},{"key":"e_1_3_11_23_2","first-page":"227","article-title":"Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: A literature review","volume":"6","author":"Velissaris D","year":"2014","unstructured":"Velissaris D, Karamouzos V, Marangos M, et al: Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: A literature review. J Clin Med Res 6:227-233, 2014","journal-title":"J Clin Med Res"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00768-6"},{"key":"e_1_3_11_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313811"},{"key":"e_1_3_11_28_2","first-page":"1024239","article-title":"Response of patients with taxane-refractory advanced urothelial cancer to enfortumab vedotin, a microtubule-disrupting agent","volume":"2023","author":"Miyake M","year":"2023","unstructured":"Miyake M, Nishimura N, Miyamoto T, et al: Response of patients with taxane-refractory advanced urothelial cancer to enfortumab vedotin, a microtubule-disrupting agent. Case Rep Urol 2023:1024239, 2023","journal-title":"Case Rep Urol"},{"key":"e_1_3_11_29_2","unstructured":"ClinicalTrials.gov: A study of SGN-B6A versus docetaxel in previously treated non-small cell lung cancer. https:\/\/www.clinicaltrials.gov\/study\/NCT06012435"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3010"},{"key":"e_1_3_11_31_2","unstructured":"ClinicalTrials.gov: This is a study to learn about how the combination of the study medicines sigvotatug vedotin plus pembrolizumab works in people with non-small cell lung cancer with high levels of PD-L1. (Be6A Lung-02). https:\/\/www.clinicaltrials.gov\/study\/NCT06758401"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:00:31Z","timestamp":1780696831000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":30,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,6,10]]}},"alternative-id":["10.1200\/JCO-25-02016"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02016","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"2025-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}